Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Glioblastoma
100%
Combination Therapy
100%
Oncolytic Parvovirus
100%
Ganglioglioma
73%
Tumor
66%
Cell Death
56%
Immune Response
40%
Virus
36%
In Vitro
33%
4 [4 (4' Chloro 2 Biphenylylmethyl) 1 Piperazinyl] N [4 [3 Dimethylamino 1 (Phenylthiomethyl)propylamino] 3 Nitrobenzenesulfonyl]benzamide
33%
Cancer Cell Line
23%
Pancreas Carcinoma
23%
Clinical Trial
23%
Parvoviridae
23%
Antineoplastic Activity
23%
Programmed Cell Death
16%
Lysosome
16%
Endoplasmic reticulum
16%
Mitochondrion
16%
Xenograft
16%
Virus Typing
16%
Secretion (Process)
16%
Oxidative Stress
16%
Adenosine Triphosphate
16%
Calcium Ion
16%
U87
16%
Glioma Cell Line
16%
Glioma Cell
16%
Immunogenic Cell Death
16%
Calreticulin
16%
Reactive Oxygen Species
16%
Blood Brain Barrier
13%
Oncolytic Virus
13%
Protoparvovirus
13%
Neoplasm
6%
Cancer Cell
6%
Tumor Microenvironment
6%
Overall Survival
6%
Virus Replication
6%
Tumor Necrosis
6%
H-1 Parvovirus
6%
Oncolytic Virotherapy
6%
Nanoparticle
6%
Lung
6%
Intracranial Tumor
6%
Cancer
6%
Keyphrases
BH3 Mimetics
66%
H-1PV
66%
Oncolytic Adenovirus
66%
Glioblastoma
66%
ABT-737
66%
H-1 Parvovirus
66%
Novel Combination Therapy
66%
Co-treatment
33%
Oncosuppression
13%
Single Treatment
13%
Rat Model
13%
Human Glioma
13%
Cell Death Pathways
13%
Glioma
13%
Combination Protocol
6%
Grant Proposal
6%
Intracellular Ca2+ Release
6%
In Vivo Rat Model
6%
Human Pancreatic Carcinoma
6%
ATP Release
6%
Parvovirus
6%
Cancer Cell Lines
6%
Calreticulin
6%
Immunogenic Cell Death
6%
Surface Exposure
6%
Oncolytic
6%
Glioma Cells
6%
Clinical Trials
6%
Oncolytic Activity
6%
Escalating Dose
6%
Anticancer Immune Response
6%
Oncolysis
6%
Clinical Outcomes
6%
Antitumor Therapeutics
6%
Intratumoural
6%
Mitochondria
6%
Induced Cell Death
6%
Endoplasmic Reticulum
6%
Treatment Needs
6%
Lysosome
6%
Virus
6%
Apoptosis
6%
Anticancer Activity
6%
Antitumor Immune Response
6%
Clinically Significant
6%
Glioma Cell Lines
6%
First Year
6%
Tumor
6%
Xenograft
6%
Reactive Oxygen Species Generation
6%
Cellular Organelles
6%
New Combination Therapy
6%
Immunocompetent Rats
6%
Anticancer Potential
6%
Wild Type Virus
6%
New Therapies
6%
Well Tolerated
6%
Oxidative Stress
6%
Further Development
6%
Safety Profile
6%
HMGB1 Release
6%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Glioblastoma
100%
Oncolytic Parvovirus
100%
Virus
55%
Rat Model
50%
Glioma
33%
Malignant Neoplasm
27%
4 [4 (4' Chloro 2 Biphenylylmethyl) 1 Piperazinyl] N [4 [3 Dimethylamino 1 (Phenylthiomethyl)propylamino] 3 Nitrobenzenesulfonyl]benzamide
22%
Parvoviridae
19%
Pancreas Carcinoma
19%
Clinical Trial
19%
Blood-Brain Barrier
16%
Oncolytic Virus
16%
Protoparvovirus
16%
Adenosine Triphosphate
11%
Calreticulin
11%
Calcium Ion
11%
Reactive Oxygen Metabolite
11%
Immunogenic Cell Death
11%
Nanoparticle
8%
Virotherapy
8%
Intracranial Tumor
8%
Neoplasm
8%
Tumor Necrosis
8%
Overall Survival
8%
H-1 Parvovirus
8%
Tumor Microenvironment
8%